"There are real safety concerns, which are difficult to answer. There's also a real need for antibiotics – especially oral antibiotics – for organisms that are becoming more and more resistant. This is the balance that we have to make, and we have to accept that medications have side effects."
Lindsey Baden, of Brigham and Women's Hospital, Dana-Farber Cancer Institute and Harvard Medical School, chair, FDA Antimicrobial Drugs Advisory Committee panel on the efficacy of Cempra Inc.'s solithromycin to treat community-acquired bacterial pneumonia

"The capability to isolate and interrogate long RNA, derived from liquid biopsies, will yield greater insight into both therapeutic discovery and development, as well as diagnostic test development. We are continually developing the capabilities of our platform to develop tests that will improve patients' lives, and provide the tools to the entities developing medicine to treat disease."
John Boyce, president and CEO of Exosome Diagnostics

"Defeating cancer involves playing a high-stakes game of biological chess. When we make a move with a therapy, cancer often responds with a counter-move by finding a way to become resistant. The key will be learning from clinical experience, so that we know cancer's moves in advance and can plan strategies to cut off its escape routes. Knowing how cancers can become resistant will ultimately require learning from hundreds of thousands of patients' experiences."
Eric Lander, founding director of the Broad Institute on a research initiative with IBM Watson Health and Harvard aimed at discovering the basis of cancer drug resistance

"Voters did their research and recognized Prop 61 was a seriously flawed measure. [It] was bad policy that would have harmed millions of patients, veterans, taxpayers and others in California."
Kathy Fairbanks, spokeswoman for the No on Prop 61 Coalition